Product Information
CARBIDOPA-LEVODOPA 25-100 TAB is a generic product labeled by TruPharma LLC, priced at $0.0759 per EA under NDC 52817039110. Its NADAC has been published 169 times since Jul 12, 2023.
FDA first approved this application on Sep 21, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 100 mg/1; mg/1
Manufacturer
TruPharma LLCNDC
52817039110
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA216505FDA Approved
9/21/2022
TE Code
AB
On Market Since
9/21/2022
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA 25-100 TAB has been published 169 times since Jul 12, 2023, and over the history we have for it it has declined 24.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0759 per EA |
|---|---|
| All-time high | $0.1014 (Jan 10, 2024) |
| All-time low | $0.0617 (Nov 20, 2024) |
| 52-week high | $0.0818 |
| 52-week low | $0.0719 |
| Median price | $0.0862 |
| Average price | $0.0845 |
| Largest weekly change | -30.7% (Nov 20, 2024) |
| Weeks tracked | 169 |
| Tracking since | Jul 12, 2023 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
TruPharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
carbidopa and levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA 25-100 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA 25-100 TAB, manufactured by TruPharma LLC, is $0.0759 per EA (NDC 52817039110), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVODOPA 25-100 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA 25-100 TAB has declined 24.4%. It has been tracked across 169 weekly CMS publications since Jul 12, 2023.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA 25-100 TAB?
Since Jul 12, 2023, the NADAC for CARBIDOPA-LEVODOPA 25-100 TAB has ranged from a low of $0.0617 (Nov 20, 2024) to a high of $0.1014 (Jan 10, 2024), with a median of $0.0862 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA 25-100 TAB?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVODOPA 25-100 TAB, is $0.0724 per EA — about 5% below CARBIDOPA-LEVODOPA 25-100 TAB.
Who manufactures CARBIDOPA-LEVODOPA 25-100 TAB?
CARBIDOPA-LEVODOPA 25-100 TAB (NDC 52817039110) is labeled by TruPharma LLC, and CMS classifies it as a generic product.